Alembic Pharmaceuticals Receives USFDA Approval for Generic Dapsone Gel
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) of Dapsone gel, 5%, a generic topical treatment for acne vulgaris. The approved product is therapeutically equivalent to Almirall's Aczone Gel. This approval adds to Alembic's portfolio, which now includes 244 USFDA ANDA approvals, enhancing its presence in the US generic pharmaceutical market.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (74/100). Lens Score 33/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- businessstandard— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
- news18— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles present a straightforward business and regulatory update without political framing. Coverage focuses on Alembic Pharmaceuticals' regulatory achievement and market implications, reflecting corporate and industry perspectives. There is no evident political bias, as the sources emphasize factual information about the drug approval and company performance.
The overall tone across the articles is neutral to mildly positive, highlighting Alembic Pharmaceuticals' regulatory success and business growth. The coverage includes factual reporting of the USFDA approval and company financials without emotional language, maintaining an informative and professional sentiment.
How 4 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.